An oral acromegaly treatmentthat’s 24 hours, one DOSE.


Crinetics is enrolling participants in studies for an investigational, ONCE-A-DAY, ORAL acromegaly treatment. See if you might be eligible to enroll.

Learn More
crin pathfndr fnl full color no description uai

To us, patients are more than the symptoms they have or the treatments they’re on. You are partners in this work. Real people with friends and families…ideas and insights…hobbies and hopes. Most of all, you have important contributions to make as we pursue solutions that will impact your life. That’s why we pledge to bring five key qualities to every patient relationship:

rick copy uai

Compassion

We will always listen with
our ears and our hearts.

Empathy

Your struggles are not lost on us
and we know how real they are.

Dedication

We embrace the perseverance
that true progress requires.

Focused Intensity

It’s the only way to do this work.

Commitment

This work is important and we give it our all.

To learn more about the relationships we build with patients, send us a message.

Compassion

We will always listen with
our ears and our hearts.

Empathy

Your struggles are not lost on us
and we know how real they are.

Dedication

We embrace the perseverance
that true progress requires.

Focused Intensity

It’s the only way to do this work.

Commitment

This work is important and we give it our all.

To learn more about the relationships we build with patients, send us a message.

Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH-dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
SST3 Agonist, Polycystic Kidney Disease
TSH Antagonist, Graves' Disease, TED
Oral GLP-1 nonpeptide, Diabetes, Obesity
Oral GIP nonpeptide, Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company
Discovery Pre-Clinical Phase 1 Phase 2 Phase 3
Paltusotine (SST2 Agonist)
Acromegaly (PATHFNDR-1)
Acromegaly (PATHFNDR-2)
Carcinoid Syndrome
Atumelnant (Oral ACTH Antagonist)
Congenital Adrenal Hyperplasia (CAH)
ACTH dependent Cushing's syndrome
PTH Antagonist, Hyperparathyroidism
Undisclosed, Polycystic Kidney
TSH Antagonist, Graves' Disease, TED
Undisclosed (Multiple), Diabetes, Obesity
SST5 Agonist, Hyperinsulinism
Radionetics, Targeted Radiotherapy | Multiple Solid-Tumor Oncology Company

Medicinal chemistry, molecular compound tests, disease processes, and other laboratory work is performed with the goal of discovering new medications.

Testing the potential new drug to gather information on efficacy, toxicity, and other key factors.

Determines the safe dosage levels of the drug candidate.

Studies how the drug candidate affects the body, how safe it is, and how it works for a specific disease.

Confirms that the drug candidate is safe and effective in the desired population.

Not shown, monitors patients over time for side effects caused by the new treatment after it has been approved and on the market.

Crinetics is pleased to actively support organizations working to improve the lives of patients with endocrine diseases, and we highly value our relationships with these special groups. If you’re interested in partnering with Crinetics in supporting any of these organizations, we can help you get in touch with them. Contact [email protected].

Acromegaly develops when a benign tumor on the pituitary gland produces too much growth hormone during adulthood. Anyone with this disease knows how debilitating and isolating it can be. The ordeal of getting monthly shots is no picnic, either. Our leading drug candidate is a once-daily pill that could make a huge impact on patients’ lives.

See what we’re up to >

New treatment options would mean more freedom instead of the same old shot every month. It would give everyone hope that they're working on something, and maybe someday a cure.

— Rick
Canandaigua, NY

New treatment options for acromegaly would be a game changer for me. I still have symptoms and would love to try a daily therapy to see if it could help.

— Traci
Columbia, SC

The research by new pharmaceutical companies is continuously ongoing. Don't be afraid to take advantage of this and jump in! I have enjoyed the opportunity to learn with the research companies. I am blessed to learn from them every day!

— Dan
S. Beloit, IL

New treatment options would mean more freedom instead of the same old shot every month. It would give everyone hope that they're working on something, and maybe someday a cure.

— Rick
Canandaigua, NY

New treatment options would mean more freedom instead of the same old shot every month. It would give everyone hope that they're working on something, and maybe someday a cure.

— Traci
Columbia, SC

The research by new pharmaceutical companies is continuously ongoing. Don't be afraid to take advantage of this and jump in! I have enjoyed the opportunity to learn with the research companies. I am blessed to learn from them every day!

— Dan
S. Beloit, IL

Congenital HI is marked by abnormally high levels of insulin that cause frequent episodes of hypoglycemia (low blood sugar). In most countries, congenital hyperinsulinism occurs approximately 1 in 25,000-50,000 new births.

Life with H.I. is like a rollercoaster ride, sometimes you’re high; sometimes you’re low but with research, funding, and new developments you never run out of hope!

— Jilani
Naples, FL

Thanks to Congenital Hyperinsulinism International (CHI) for usage rights to this photo.

After a near-total pancreatectomy at one month and his first four months in the hospital, James came home on continuous dextrose to maintain blood sugar levels. We must be constantly vigilant to ensure he's in a safe range. Despite the challenges, he's an active, smart toddler who loves to play, sing and dance.

— James
Philadelphia, PA

Thanks to Congenital Hyperinsulinism International (CHI) for usage rights to this photo.

Life with H.I. is like a rollercoaster ride, sometimes you’re high; sometimes you’re low but with research, funding, and new developments you never run out of hope!

— Jilani
Naples, FL

Thanks to Congenital Hyperinsulinism International (CHI) for usage rights to this photo.

After a near-total pancreatectomy at one month and his first four months in the hospital, James came home on continuous dextrose to maintain blood sugar levels. We must be constantly vigilant to ensure he's in a safe range. Despite the challenges, he's an active, smart toddler who loves to play, sing and dance.

— James
Philadelphia, PA

Thanks to Congenital Hyperinsulinism International (CHI) for usage rights to this photo.

Cushing’s disease is caused by a pituitary tumor that hypersecretes ACTH, leading to the production of abnormally high levels of the hormone cortisol by the adrenal glands. We estimate that approximately 10,000 people in the United States live with Cushing’s Disease.

See what we’re working on >

Better treatment options give me hope. When I learn of new medical treatments for Cushing's, I feel like Cushing's disease is finally getting the grossly overdue attention it's deserved for years.

— Sharmyn
Newport Beach, CA

Better treatment options give me hope. When I learn of new medical treatments for Cushing's, I feel like Cushing's disease is finally getting the grossly overdue attention it's deserved for years.

— Sharmyn
Newport Beach, CA

Contact Patient Advocacy


    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.